Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma, which acquired an 85% royalty interest in Theravance Biopharma Inc.’s asthma/COPD drug Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for $1.1bn in cash up front and up to $250m in additional payments contingent on the achievement of certain sales milestones anticipated to occur between 2023-2026.
Financing Quarterly Statistics, Q3 2022
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2022
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
More from Deal-Making
More from In Vivo
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.